Jacc: Cardiooncology最新文献

{"title":"Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy","authors":"Ronald Witteles MD ,&nbsp;John L. Jefferies MD, MPH ,&nbsp;Suraj Kapa MD ,&nbsp;Francesco Cappelli MD, PhD ,&nbsp;Marla B. Sultan MD, MBA ,&nbsp;Balarama Gundapaneni MS ,&nbsp;Margot K. Davis MD, MS ,&nbsp;Pablo Garcia-Pavia MD","doi":"10.1016/j.jaccao.2024.03.007","DOIUrl":"10.1016/j.jaccao.2024.03.007","url":null,"abstract":"<div><h3>Background</h3><p>Atrial fibrillation/atrial flutter (AF/AFL) are common manifestations of transthyretin amyloid cardiomyopathy (ATTR-CM) but have not been found to be predictive of mortality.</p></div><div><h3>Objectives</h3><p>This analysis aimed to examine whether baseline or historical AF/AFL at enrollment was prognostic for all-cause mortality.</p></div><div><h3>Methods</h3><p>In the ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial), a 30-month study of tafamidis vs placebo for ATTR-CM, AF/AFL was evaluated as an independent prognostic factor for all-cause mortality using Cox proportional hazards modelling. The impact of AF/AFL on tafamidis efficacy was explored by adding an interaction term for AF/AFL status and treatment.</p></div><div><h3>Results</h3><p>ATTR-ACT enrolled 441 patients with ATTR-CM (median age 75 years; 90% male); 314 (71.2%) had baseline or historical AF/AFL at enrollment. AF/AFL was an independent prognostic factor for all-cause mortality after adjusting for covariates prespecified in the ATTR-ACT model (treatment, genotype, New York Heart Association functional class; HR: 0.550; 95% CI: 0.368-0.821) but not in an expanded stepwise model selection analysis including 23 covariates (blood urea nitrogen and N-terminal pro–B-type natriuretic peptide concentration, 6-minute walk test distance, genotype, treatment, and global longitudinal strain were prognostic [<em>P</em> &lt; 0.01]). The interactions between tafamidis treatment and AF/AFL for all-cause mortality (<em>P</em> = 0.33) and changes in Kansas City Cardiomyopathy Questionnaire Overall Summary score (<em>P</em> = 0.83) and 6-minute walk test distance (<em>P</em> = 0.82) were not significant.</p></div><div><h3>Conclusions</h3><p>In ATTR-ACT, baseline or historical AF/AFL was prognostic for all-cause mortality in analyses with limited adjustment but not after accounting for additional indicators of disease severity. Baseline or historical AF/AFL did not impact the efficacy of tafamidis treatment. (Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy [ATTR-ACT]; <span><span>NCT01994889</span><svg><path></path></svg></span>)</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 592-598"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266608732400139X/pdfft?md5=2bcd89bda9a88b279326659fce90ee15&pid=1-s2.0-S266608732400139X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy","authors":"Nowell M. Fine MD, SM","doi":"10.1016/j.jaccao.2024.05.016","DOIUrl":"10.1016/j.jaccao.2024.05.016","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 599-601"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002205/pdfft?md5=28182e88f5a3c51525dec62f7d328787&pid=1-s2.0-S2666087324002205-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full Issue PDF","authors":"","doi":"10.1016/S2666-0873(24)00261-8","DOIUrl":"10.1016/S2666-0873(24)00261-8","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages I-CLX"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002618/pdfft?md5=6570b0cd1d87926630142b8ef929f6c1&pid=1-s2.0-S2666087324002618-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Light-Chain Pericardial Amyloidosis Emerging Alongside Variant Transthyretin Cardiac Amyloidosis","authors":"Alexander H. Gunn MD ,&nbsp;Johana Fajardo DNP ,&nbsp;Louis Dibernardo MD ,&nbsp;Carolyn Glass MD ,&nbsp;Fawaz Alenezi MD ,&nbsp;Ravi Karra MD ,&nbsp;Ellen D. McPhail MD ,&nbsp;Cristiana Costa Chase DO ,&nbsp;Michel G. Khouri MD","doi":"10.1016/j.jaccao.2024.04.002","DOIUrl":"10.1016/j.jaccao.2024.04.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 612-616"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324001467/pdfft?md5=f46fbc76d6a79bf174a7225c5a692b99&pid=1-s2.0-S2666087324001467-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mediterranean Diet Is Associated With Lower All-Cause and Cardiovascular Mortality Among Long-Term Cancer Survivors","authors":"Marialaura Bonaccio PhD ,&nbsp;Augusto Di Castelnuovo PhD ,&nbsp;Simona Costanzo PhD ,&nbsp;Emilia Ruggiero PhD ,&nbsp;Simona Esposito MSc ,&nbsp;Teresa Panzera BSc ,&nbsp;Chiara Cerletti PhD ,&nbsp;Maria Benedetta Donati MD, PhD ,&nbsp;Giovanni de Gaetano MD, PhD ,&nbsp;Licia Iacoviello MD, PhD","doi":"10.1016/j.jaccao.2024.05.012","DOIUrl":"10.1016/j.jaccao.2024.05.012","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 602-604"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002084/pdfft?md5=162cc2097081edc9d019deb80b882cc2&pid=1-s2.0-S2666087324002084-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Certainty of Evidence on Efficacy and Safety of Anticoagulants for Cancer-Associated Thrombosis","authors":"Faizan Khan PhD,&nbsp;Marc Carrier MD,&nbsp;Bram Rochwerg MD","doi":"10.1016/j.jaccao.2024.03.014","DOIUrl":"10.1016/j.jaccao.2024.03.014","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 622-623"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002138/pdfft?md5=99de16470585e53cfaaafab04d244bdc&pid=1-s2.0-S2666087324002138-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141702553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy","authors":"Sara-Lise Busschaert MSc ,&nbsp;Eva Kimpe MSc ,&nbsp;Thierry Gevaert PhD ,&nbsp;Mark De Ridder PhD, MD ,&nbsp;Koen Putman PhD","doi":"10.1016/j.jaccao.2024.04.009","DOIUrl":"10.1016/j.jaccao.2024.04.009","url":null,"abstract":"<div><h3>Background</h3><p>Deep inspiration breath hold (DIBH) is an effective technique for reducing heart exposure during radiotherapy for left-sided breast cancer. Despite its benefits, cost considerations and its impact on workflow remain significant barriers to widespread adoption.</p></div><div><h3>Objectives</h3><p>This study aimed to assess the cost-effectiveness of DIBH and compare its operational, financial, and clinical outcomes with free breathing (FB) in breast cancer treatment.</p></div><div><h3>Methods</h3><p>Treatment plans for 100 patients with left-sided breast cancer were generated using both DIBH and FB techniques. Dosimetric data, including the average mean heart dose, were calculated for each technique and used to estimate the cardiotoxicity of radiotherapy. A state-transition microsimulation model based on SCORE2 (Systematic Coronary Risk Evaluation) algorithms projected the effects of DIBH on cardiovascular outcomes and quality-adjusted life-years (QALYs). Costs were calculated from a provider perspective using time-driven activity-based costing, applying a willingness-to-pay threshold of €40,000 for cost-effectiveness assessment. A discrete event simulation model assessed the impacts of DIBH vs FB on throughput and waiting times in the radiotherapy workflow.</p></div><div><h3>Results</h3><p>In the base case scenario, DIBH was associated with an absolute risk reduction of 1.72% (95% CI: 1.67%-1.76%) in total cardiovascular events and 0.69% (95% CI: 0.67%-0.72%) in fatal cardiovascular events over 20 years. Additionally, DIBH was estimated to provide an incremental 0.04 QALYs (95% CI: 0.05-0.05) per left-sided breast cancer patient over the same time period. However, DIBH increased treatment times, reducing maximum achievable throughput by 12.48% (95% CI: 12.36%-12.75%) and increasing costs by €617 per left-sided breast cancer patient (95% CI: €615-€619). The incremental cost-effectiveness ratio was €14,023 per QALY.</p></div><div><h3>Conclusions</h3><p>Despite time investments, DIBH is cost-effective in the Belgian population. The growing adoption of DIBH may benefit long-term cardiovascular health in breast cancer survivors.</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 514-525"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002059/pdfft?md5=ef3a028ea334721f506bbe0608f82cfc&pid=1-s2.0-S2666087324002059-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141709101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults","authors":"David G. Gent MBChB (Hons) ,&nbsp;Muhammad Saif MD ,&nbsp;Rebecca Dobson MD ,&nbsp;David J. Wright MD","doi":"10.1016/j.jaccao.2024.06.004","DOIUrl":"10.1016/j.jaccao.2024.06.004","url":null,"abstract":"<div><p>The use of hematopoietic cell transplantation (HCT) has expanded in the last 4 decades to include an older and more comorbid population. These patients face an increased risk of cardiovascular disease after HCT. The risk varies depending on several factors, including the type of transplant (autologous or allogeneic). Many therapies used in HCT have the potential to be cardiotoxic. Cardiovascular complications after HCT include atrial arrhythmias, heart failure, myocardial infarction, and pericardial effusions. Before HCT, patients should undergo a comprehensive cardiovascular assessment, with ongoing surveillance tailored to their individual level of cardiovascular risk. In this review, we provide an overview of cardiotoxicity after HCT and outline our approach to risk assessment and ongoing care.</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 475-495"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002254/pdfft?md5=558e4c6d9d6c3badd123dba5ccbab081&pid=1-s2.0-S2666087324002254-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Macrotroponin Complexes and Their Impact on Cardiac Troponin Measurements","authors":"Inbar Nardi-Agmon MD, MPH ,&nbsp;Ashley Di Meo PhD ,&nbsp;Leo Lam MBChB ,&nbsp;Campbell Kyle MBChB, PhD ,&nbsp;Husam Abdel-Qadir MD, PhD ,&nbsp;Eitan Amir MD, PhD ,&nbsp;Paaladinesh Thavendiranathan MD, SM","doi":"10.1016/j.jaccao.2024.06.002","DOIUrl":"10.1016/j.jaccao.2024.06.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 608-611"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002229/pdfft?md5=4ed24702d6fc374028f1459b88bed3ac&pid=1-s2.0-S2666087324002229-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Benign Metastatic Leiomyoma","authors":"","doi":"10.1016/j.jaccao.2024.03.011","DOIUrl":"10.1016/j.jaccao.2024.03.011","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 617-621"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324001443/pdfft?md5=223627642c0462ed5b6de646943a7226&pid=1-s2.0-S2666087324001443-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141058048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}